, Tracking Stock Market Picks
Enter Symbol:
Rating: ALKS

Alkermes, Inc. (NASDAQ: ALKS) downgraded to Underweight by Morgan Stanley

Thursday,  Jan 21, 2016  5:25 PM ET by Lynn Gilbert

Morgan Stanley downgraded Alkermes, Inc. (NASDAQ: ALKS) to Underweight. Previously,
Morgan Stanley rated Alkermes, Inc. (NASDAQ: ALKS) to Equal-Weight on 10/01/2013, when the stock price was valued at $32.87.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Morgan Stanley Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy